top stories

Es­pe­ri­on's goldilocks cho­les­terol fight­er wins FDA ap­proval — will its 'tra­di­tion­al' pric­ing ap­proach spur adop­tion?

Yesterday
Pharma
Regulatory

The fourth CGRP mi­graine drug is here. Time for Lund­beck to prove it's worth $2B

Yesterday
Pharma
Regulatory

UP­DAT­ED: A space odyssey for new an­tibi­otics: MIT's ma­chine learn­ing ap­proach

2 days ago
AI
R&D

Gilead los­es two more patent chal­lenges on HIV pill, set­ting up court­room fight in Delaware

2 days ago
R&D

Latest

Most read

Gene ther­a­py pi­o­neer Kathy High has left Spark af­ter com­plet­ing $4.3B union with Roche

2 days ago
Cell/Gene Tx
People

Gen­fit de­lays high-stakes PhI­II NASH read­out; Bris­tol-My­ers grabs first Op­di­vo OK in esophageal can­cer

2 days ago
Protocols

Bank­rupt an­tibi­otics mak­er Ar­a­digm turns to old part­ner/in­vestor for fi­nal $3M fire sale

2 days ago
Deals

DB­V's peanut pre­ven­tion patch ap­proach­es key stage of ap­proval process

2 days ago
R&D

An­to­nio Gual­ber­to starts post-Ku­ra ca­reer at Ei­sai sub­sidiary H3; eF­FEC­TOR co-founder Siegfried Re­ich jumps to ...

2 days ago
Peer Review

Say good­bye to Toca­gen, strug­gling brain can­cer biotech to re­verse merge with Forte Bio­sciences

2 days ago
Deals
see latest stream
People

Fresh off $100M round, GV-backed re­al-world da­ta start­up woos Duke re­searcher as CMO

3 days ago

Mer­ck los­es its chief dig­i­tal of­fi­cer, spot­light­ing tal­ent hunt for the hottest ti­tle in Big Phar­ma

3 days ago

Eli Lil­ly vet Ker­ry Blan­chard takes the helm at one of Chi­na's top deal­mak­ers, steer­ing to­ward first ap­provals

3 days ago
Startups

Drug dis­cov­ery in HD: Ox­ford spin­of­f's mass spec­trom­e­try ap­proach scores fresh fund­ing

5 days ago

Corey Good­man mar­shals $105M mega-round for his CD47 up­start, look­ing to break new ground in PhII

Last week

From mice to dogs, and some­day man: George Church's gene ther­a­py cock­tail for ag­ing-re­lat­ed dis­eases

3 weeks ago
Deals

Don't let Ab­b­Vie fool FTC with an easy di­vesti­ture, plead crit­ics in lat­est at­tack on $63B Al­ler­gan buy­out

3 days ago

TCR-fo­cused Im­mat­ics adds an­oth­er mar­quee name to its list of part­ners: GSK

3 days ago

UP­DAT­ED: DuPont makes an­oth­er for­ay in­to drug R&D, throw­ing its name in­to the mi­cro­bio­me hat

4 days ago
IPOs

As sick­le cell pa­tients find new op­tions, NEA-found­ed Imara pitch­es mid-stage al­ter­na­tive for $86M IPO

5 days ago

The RAS rush: Rev­o­lu­tion Med­i­cines bags re­mark­able $238M IPO raise, more than dou­bling orig­i­nal goal

Last week

Par­ty on: Base edit­ing start­up, com­pu­ta­tion­al drug dis­cov­ery ex­perts and CRO bag close to $2B to­tal on their way to ...

3 weeks ago

Premium storiesSee all

The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

5 days ago
Venture

The top 10 bio­phar­ma pipeline blowups, set­backs and sna­fus for H2 2019

Last week
Bioregnum

Weak pipeline? Why, Sanofi ex­ecs are sud­den­ly over the moon about their prospects

3 weeks ago
Bioregnum
R&D

The pow­er of prece­dent: How a one-off de­ci­sion by Janet Wood­cock es­tab­lished an un­in­tend­ed fast path­way at the FDA ...

3 weeks ago
Bioregnum

Don't missSee all

Speedy re­view and no ad­comm for Bio­Mar­in's pi­o­neer­ing he­mo­phil­ia gene ther­a­py

2 days ago
Cell/Gene Tx
Regulatory

Auste­do, Teva's bright spot as it ex­e­cutes turn­around, fails two Touret­te's tri­als

3 days ago
Pharma

For two decades, a new vac­cine tech­nol­o­gy has been slow­ly ap­proach­ing prime time. Now, can it stop a pan­dem­ic?

4 days ago
R&D

Bris­tol-My­ers shrugs off an­oth­er Op­di­vo com­bo flop as $1.74B deal goes pfffft

4 days ago
R&D

Endpoints Standouts

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

Last month
Pharma
Special

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

3 months ago
People
R&D

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

2 months ago
Publisher's note

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

4 months ago

Peer review See all

Feb
14

Palleon's first CSO ex­plains how they (and she) got here; En­ter­prise taps Roche and No­var­tis vet David Mor­ris as CMO

Feb
7

Craig Bas­son tells us why he leapt from NI­BR to Boston Phar­ma; Ex-BMS Part­ner Cy­tomX finds new CMO in Al­li­son Han­nah

Jan
31

Mod­er­na woos tri­al vet Melanie Ivars­son to the se­nior R&D team; Ex-Roche CMO San­dra Horn­ing joins Gilead board

Jan
24

Di­a­betes-fo­cused Pox­el names Eli Lil­ly vet David Moller as CSO; Ac­celeron's CBO hops ship to lead start­up

Jan
17

Pe­ter Ciriel­lo takes over the reins at Vy­gon USA; Mirum Phar­ma­ceu­ti­cals taps Ian Clements to the role of CFO

R&D channel feed

3 days ago

Armed with a batch of pos­i­tive bio­mark­er da­ta, a rare dis­ease play­er reaps $88M for the next big push in the clin­ic

Omega Funds and Abing­worth teamed up to lead an $88 mil­lion round for Spruce, which is pri­mar­i­ly fo­cused on de­vel­op­ing tildac­er­font to treat clas­sic con­gen­i­tal adren­al hy­per­pla­sia. The ...

READ MORE

Cel­lec­tis boosts its cof­fers in re­vised off-the-shelf CAR-T deal with Servi­er

4 days ago

Astel­las fol­lows up $3B gene ther­a­py buy­out with $109M plan to ac­cel­er­ate a man­u­fac­tur­ing boom

4 days ago
latest in R&D

He built a MERS treat­ment in 6 months and then the best Ebo­la drug. Now Chris­tos Kyrat­sous turns his sights on Covid-19

5 days ago

FDA goes on high alert as coro­n­avirus rais­es threat to drug man­u­fac­tur­ing and clin­i­cal tri­als grind to a halt

5 days ago
Coronavirus
Regulatory

War­ren Buf­fett gets a dou­ble take as the in­vest­ment pow­er­house set­tles on its first biotech in­vest­ment

5 days ago

If you were a can­cer pa­tient, where would you rather be — the Unit­ed States or Eu­rope?

Last week

As­traZeneca's Chi­nese in­vest­ment bank part­ner rais­es $229M for its own new fund — and it's all about the coro­n­avirus

Last week
Coronavirus
see latest stories

Pharma channel feed

4 days ago

As blue­bird makes com­mer­cial progress in Eu­rope, US ap­pli­ca­tion for Zyn­te­glo suf­fers de­lay

Af­ter shock­ing Wall Street with a $1.8 mil­lion price tag for its gene ther­a­py Zyn­te­glo in Eu­rope — blue­bird bio on Tues­day re­vealed that it now ex­pects to com­plete its US ap­pli­ca­tion to mar­ket ...

READ MORE

Phar­ma­co­ge­net­ics: FDA re­leas­es ta­ble of gene-drug in­ter­ac­tions

2 days ago
Regulatory

For­mer No­var­tis ex­ec pleads guilty to gener­ic price fix­ing

5 days ago
latest in Pharma

New en­tries, price hikes spur changes among the 20 most ex­pen­sive drugs — though not the kind politi­cians like to see

Last week

Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

Last week
Coronavirus
R&D

The list of the 11 block­busters-to-be in line for a 2020 launch high­light agony and ec­sta­sy of drug R&D

Last week

8 years af­ter its OK, Ei­sai yanks its flail­ing obe­si­ty drug from the mar­ket af­ter FDA flagged high­er can­cer rate

Last week
Regulatory

Roche scores its first PD-L1 win in Chi­na, go­ing straight for SCLC niche

Last week
China
see latest stories